CRYSTALLINE FORMS OF A MONOACYLGLYCEROL LIPASE INHIBITOR

Described herein is new crystalline forms of the MAGL inhibitor 1-(1-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carbonyl)-1H-pyrazole-3-carboxylic acid, or a pharmaceutically acceptable salt thereof. L'invention concerne de nouvelles formes cristallines de l...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	ANDREW, Samuel George, EDWARDS, Richard James, GRICE, Cheryl A, JUHL, Martin, BUZARD, Daniel J, GANCEDO, Susana Del Rio, PATTERSON, Adam Ross, VETTER, Thomas, WIENER, John J.M, ALLAN, Amy, CINCOTTI, Antonio, LOPEZ DE DIEGO, Heidi
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Described herein is new crystalline forms of the MAGL inhibitor 1-(1-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carbonyl)-1H-pyrazole-3-carboxylic acid, or a pharmaceutically acceptable salt thereof. L'invention concerne de nouvelles formes cristallines de l'inhibiteur de MAGL 1-(1-(2-(pyrrolidin-1-yl)-4-(trifluorométhyl)benzyl)-1,8-diazaspiro[4,5]décane-8-carbonyl)-1H-pyrazole-3-carboxylique, ou d'un sel pharmaceutiquement acceptable de celui-ci.